SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $60,680,000 | +167.3% | 2,772,062 | +133.3% | 4.67% | +157.1% |
Q3 2021 | $22,705,000 | +11.3% | 1,188,135 | 0.0% | 1.82% | -3.4% |
Q2 2021 | $20,400,000 | -36.4% | 1,188,135 | -17.2% | 1.88% | -26.9% |
Q1 2021 | $32,088,000 | +2.7% | 1,435,045 | +2.1% | 2.57% | +7.0% |
Q4 2020 | $31,248,000 | +60.4% | 1,405,045 | +6.4% | 2.41% | +37.6% |
Q3 2020 | $19,484,000 | -0.4% | 1,320,045 | 0.0% | 1.75% | +1.8% |
Q2 2020 | $19,563,000 | +80.0% | 1,320,045 | +33.2% | 1.72% | +39.4% |
Q1 2020 | $10,868,000 | – | 990,711 | – | 1.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |